<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107451">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01712763</url>
  </required_header>
  <id_info>
    <org_study_id>C06/2012</org_study_id>
    <nct_id>NCT01712763</nct_id>
  </id_info>
  <brief_title>Degarelix in the Treatment of Endometriosis Recurrence</brief_title>
  <official_title>Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long acting GnRH antagonist degarelix will be tested for the treatment of women with
      endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom
      disappearance and disease free time during follow-up will be the outcomes for establishing
      which medical treatment is the best in endometriosis recurrence treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing
      recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH
      antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist
      and strongly suppress LH secretion and thecal cell activity may show a better effects on
      endometrial implants than GnRH agonist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>disease free time</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time without pain symptoms due to the disease recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of disappearance pain</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time needed during treatment to improve the pain symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>reduction of endometriosis lesions</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>endometriosis lesions regression during treatment evidenced by MRI scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 women will be treated with degarelix 80mg in one administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Goserelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>goserelin 3.6mg monthly for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>degarelix</intervention_name>
    <description>50 women will be treated with degarlix 80 mg, in only one administration covering three months</description>
    <arm_group_label>Degarelix</arm_group_label>
    <other_name>firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <description>50 women will be treated with decapeptyl 3.6 every month for three months</description>
    <arm_group_label>Goserelin</arm_group_label>
    <other_name>decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women affected by endometriosis showing recurrence of pain symptoms

          -  previous surgery for endometriosis

        Exclusion Criteria:

          -  presence of other systemic diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARCO SBRACIA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARCO SBRACIA, MD</last_name>
    <phone>+39065810461</phone>
    <email>marcandrea@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FABIO SCARPELLINI, MD</last_name>
    <phone>+39068848013</phone>
    <email>quelidebercia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARCO SBRACIA, MD</last_name>
      <phone>+39065810461</phone>
      <email>marcandrea@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>FABIO SCARPELLINI, MD</last_name>
      <phone>+39068848013</phone>
      <email>quelidebercia@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>MARCO SBRACIA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>long acting GnRH antagonist</keyword>
  <keyword>Degarelix</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Pelvic Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
